This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
|Condition||Primary Open Angle Glaucoma, Ocular Hypertension|
|Treatment||Brinzolamide ophthalmic suspension, Azopt®|
|Clinical Study Identifier||NCT05022004|
|Sponsor||Sun Pharmaceutical Industries Limited|
|Last Modified on||16 March 2022|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.Learn more
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.Learn more
No annotations made yet
Congrats! You have your own personal workspace now.